Treatment of advanced thyroid cancer with targeted therapies: ten years of experience
Open accessThe DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
Thyroid cancer is rare, but it is the most frequent endocrine malignancy. Its prognosis is generally favorable, especially in cases of well-differentiated thyroid cancers (DTCs), such as papillary and follicular cancers, which have survival rates of approximately 95% at 40 years. However, 15–20% of cases became radioiodine refractory (RAI-R), and until now, no other treatments have been effective. The same problems are found in cases of poorly differentiated (PDTC) and anaplastic (ATC) thyroid cancers and in at least 30% of medullary thyroid cancer (MTC) cases, which are very aggressive and not sensitive to radioiodine. Tyrosine kinase inhibitors (TKIs) represent a new approach to the treatment of advanced cases of RAI-R DTC, MTC, PDTC, and, possibly, ATC. In the past 10 years, several TKIs have been tested for the treatment of advanced, progressive, and RAI-R thyroid tumors, and some of them have been recently approved for use in clinical practice: sorafenib and lenvatinib for DTC and PDTC and vandetanib and cabozantinib for MTC. The objective of this review is to present the current status of the treatment of advanced thyroid cancer with the use of innovative targeted therapies by describing both the benefits and the limits of their use based on the experiences reported so far. A comprehensive analysis and description of the molecular basis of these therapies, as well as new therapeutic perspectives, are reported. Some practical suggestions are given for both the choice of patients to be treated and their management, with particular regard to the potential side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713 · cited 1×
“Since 2001, when the first TKI (imatinib) was approved for the treatment of chronic myelogenous leukemia, many of these drugs have been studied for the treatment of thyroid cancer (Druker et al. 2001).”
BackgroundLenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Self-citationDurante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J. D., De Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,675 · cited 1×
“However, in approximately 10% of cases, the patients have an advanced stage of the cancer at the time of diagnosis, with local invasion and/or distant metastases in the lungs (50%), bone (25%), lungs and bone (20%), and other sites (5%), and curing these cases with conventional therapeutic procedures is unlikely (Dura…”
BackgroundBrose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Self-citationWells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Self-citationMolecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426 · cited 17×
“Interestingly, the activation of this pathway seems to upregulate the same proteins that are overexpressed by the MAPK pathway, and the oncogenic mutations that act through the MAPK pathway (i.e., BRAFV600E, RET/PTC rearrangements, and RAS) cause the activation of NF-κB (Xing 2013).”
BackgroundInfluentialCabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
Self-citationHayat, M. J., Howlader, N., Reichman, M. E., & Edwards, B. K. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-20 · Cited by 1,096
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,042
Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
Xing, M., Alzahrani, A. S., Carson, K. A., Viola, D., Elisei, R., Bendlova, B., Yip, L., Mian, C., Vianello, F., Tuttle, R. M., et al. (2013) · JAMA · doi:10.1001/jama.2013.3190 · Cited by 940
Self-citationSelumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., Zanzonico, P. B., Haque, S., Gavane, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843
KIF5B-RET fusions in lung adenocarcinoma
Kohno, T., Ichikawa, H., Totoki, Y., Yasuda, K., Hiramoto, M., Nammo, T., Sakamoto, H., Tsuta, K., Furuta, K., Shimada, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2644 · Cited by 834
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Gupta-Abramson, V., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3279 · Cited by 680
Nikiforov, Y. E., Rowland, J. M., Bove, K. E., Monforte-Muñoz, H., & Fagin, J. A. (1997) · PubMed · Cited by 666
Blocking of EGF-Dependent Cell Proliferation by EGF Receptor Kinase Inhibitors
Yaish, P., Gazit, A., Gilon, C., & Levitzki, A. (1988) · Science · doi:10.1126/science.3263702 · Cited by 587
Robbins, R. J., Wan, Q., Grewal, R. K., Reibke, R., Gonen, M., Strauss, H. W., Tuttle, R. M., Drucker, W., & Larson, S. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1534 · Cited by 587
Rini, B. I., Cohen, D. P., Lu, D. R., Chen, I., Hariharan, S., Gore, M. E., Figlin, R. A., Baum, M. S., & Motzer, R. J. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr128 · Cited by 579
Carlomagno, F., Vitagliano, D., Guida, T., Ciardiello, F., Tortora, G., Vecchio, G., Ryan, A. J., Fontanini, G., Fusco, A., & Santoro, M. M. (2002) · PubMed · Cited by 569
Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4145 · Cited by 550
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
Kloos, R. T., Ringel, M. D., Knopp, M. V., Hall, N. C., King, M., Stevens, R., Liang, J., Wakely, P. E., Vasko, V. V., Saji, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2717 · Cited by 541
Elisei, R., Ugolini, C., Viola, D., Lupi, C., Biagini, A., Giannini, R., Romei, C., Miccoli, P., Pinchera, A., & Basolo, F. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0607 · Cited by 528
Self-citationAssociation Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer
Xing, M., Alzahrani, A. S., Carson, K. A., Shong, Y. K., Kim, T. Y., Viola, D., Elisei, R., Bendlová, B., Yip, L., Mian, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.8253 · Cited by 523
Self-citationBAY 43-9006 Inhibition of Oncogenic RET Mutants
Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S. M., & Santoro, M. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj069 · Cited by 476
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Sherman, S. I., Wirth, L. J., Droz, J.-P., Hofmann, M., Bastholt, L., Martins, R. G., Licitra, L., Eschenberg, M. J., Sun, Y.-N., Juan, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075853 · Cited by 470
RET tyrosine kinase signaling in development and cancer
Arighi, E., Borrello, M. G., & Sariola, H. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.05.010 · Cited by 468
Ohashi, K., Sequist, L. V., Arcila, M. E., Moran, T., Chmielecki, J., Lin, Y.-L., Pan, Y., Wang, L., de Stanchina, E., Shien, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203530109 · Cited by 441
Bible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., Rubin, J., Sideras, K., Morris, J. C., McIver, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70203-5 · Cited by 421
Knauf, J. A., Ma, X., Smith, E. P., Zhang, L., Mitsutake, N., Liao, X.-H., Refetoff, S., Nikiforov, Y. E., & Fagin, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0047 · Cited by 414
Chakravarty, D., Santos, E., Ryder, M., Knauf, J. A., Liao, X.-H., West, B. L., Bollag, G., Kolesnick, R., Thin, T. H., Rosen, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46382 · Cited by 391
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
Smallridge, R. C., Marlow, L. A., & Copland, J. A. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-08-0154 · Cited by 390
Liu, Z., Hou, P., Ji, M., Guan, H., Studeman, K., Jensen, K., Vasko, V., El-Naggar, A. K., & Xing, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0273 · Cited by 390
Definition and management of radioactive iodine-refractory differentiated thyroid cancer
Schlumberger, M., Brose, M., Elisei, R., Leboulleux, S., Luster, M., Pitoia, F., & Pacini, F. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70215-8 · Cited by 377
Self-citationRiesco-Eizaguirre, G., Gutiérrez-Martínez, P., García-Cabezas, M. A., Nistal, M., & Santisteban, P. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01119 · Cited by 376
Leboulleux, S., Bastholt, L., Krause, T., de la Fouchardiere, C., Tennvall, J., Awada, A., Gómez, J. M., Bonichon, F., Leenhardt, L., Soufflet, C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70335-2 · Cited by 375
Rong, S., Segal, S., Anver, M., Resau, J. H., & Vande Woude, G. F. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4731 · Cited by 363
Schlumberger, M. J., Elisei, R., Bastholt, L., Wirth, L. J., Martins, R. G., Locati, L. D., Jarzab, B., Pacini, F., Daumerie, C., Droz, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7815 · Cited by 340
Self-citationMDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
Finke, J., Ko, J., Rini, B., Rayman, P., Ireland, J., & Cohen, P. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.030 · Cited by 281
Elisei, R., Romei, C., Vorontsova, T., Cosci, B., Veremeychik, V., Kuchinskaya, E., Basolo, F., Demidchik, E. P., Miccoli, P., Pinchera, A., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7678 · Cited by 275
Self-citationLaure Giraudet, A., Al Ghulzan, A., Aupérin, A., Leboulleux, S., Chehboun, A., Troalen, F., Dromain, C., Lumbroso, J., Baudin, E., & Schlumberger, M. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0667 · Cited by 272
Miyauchi, A., Kudo, T., Miya, A., Kobayashi, K., Ito, Y., Takamura, Y., Higashiyama, T., Fukushima, M., Kihara, M., Inoue, H., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0355 · Cited by 265
Carlomagno, F., Guida, T., Anaganti, S., Vecchio, G., Fusco, A., Ryan, A. J., Billaud, M., & Santoro, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207810 · Cited by 258
Molecular Diagnostics of Thyroid Tumors
Nikiforov, Y. E. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0664-rair.1 · Cited by 257
Schlumberger, M., Jarzab, B., Cabanillas, M. E., Robinson, B., Pacini, F., Ball, D. W., McCaffrey, J., Newbold, K., Allison, R., Martins, R. G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1127 · Cited by 247
Self-citationRET Oncogene Activation in Papillary Thyroid Carcinoma
Tallini, G., Asa, S. L., & Fuller, G. N. (2001) · Advances in Anatomic Pathology · doi:10.1097/00125480-200111000-00005 · Cited by 223 · cited 1×
“…r DOI: 10.1530/ERC-15-0555 http://erc.endocrinology-journals.org 2016 Society for Endocrinology Printed in Great Britain Published by Bioscientifica Ltd. activation of RET in the follicular cells in which it is not usually expressed or is only expressed at a very low level (Tallini & Asa 2001).”
BackgroundInfluentialPhase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid
Savvides, P., Nagaiah, G., Lavertu, P., Fu, P., Wright, J. J., Chapman, R., Wasman, J., Dowlati, A., & Remick, S. C. (2013) · Thyroid · doi:10.1089/thy.2012.0103 · Cited by 219
Santarpia, L., El-Naggar, A. K., Cote, G. J., Myers, J. N., & Sherman, S. I. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1076 · Cited by 208
Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
Nakaoku, T., Tsuta, K., Ichikawa, H., Shiraishi, K., Sakamoto, H., Enari, M., Furuta, K., Shimada, Y., Ogiwara, H., Watanabe, S.-I., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0107 · Cited by 206
Cabanillas, M. E., Schlumberger, M., Jarzab, B., Martins, R. G., Pacini, F., Robinson, B., McCaffrey, J. C., Shah, M. H., Bodenner, D. L., Topliss, D., et al. (2015) · Cancer · doi:10.1002/cncr.29395 · Cited by 186
Self-citationPacini, F. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.12.5686 · Cited by 185
Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series
Ciampi, R., Mian, C., Fugazzola, L., Cosci, B., Romei, C., Barollo, S., Cirello, V., Bottici, V., Marconcini, G., Rosa, P. M., et al. (2013) · Thyroid · doi:10.1089/thy.2012.0207 · Cited by 178
Self-citationDeandreis, D., Al Ghuzlan, A., Leboulleux, S., Lacroix, L., Garsi, J. P., Talbot, M., Lumbroso, J., Baudin, E., Caillou, B., Bidart, J. M., et al. (2011) · Endocrine Related Cancer · doi:10.1677/erc-10-0233 · Cited by 177
A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer
Bible, K. C., Suman, V. J., Menefee, M. E., Smallridge, R. C., Molina, J. R., Maples, W. J., Karlin, N. J., Traynor, A. M., Kumar, P., Goh, B. C., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1520 · Cited by 175
Gene Methylation in Thyroid Tumorigenesis
Xing, M. (2007) · Endocrinology · doi:10.1210/en.2006-0927 · Cited by 174 · cited 1×
“In addition to these genetic alterations, epigenetic abnormalities have been described to play an important role in human cancer and in thyroid cancer tumorigenesis, cell differentiation, and proliferation (Xing 2007).”
BackgroundBRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma
Salvatore, G., De Falco, V., Salerno, P., Nappi, T. C., Pepe, S., Troncone, G., Carlomagno, F., Melillo, R. M., Wilhelm, S. M., & Santoro, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2378 · Cited by 172
Abubaker, J., Jehan, Z., Bavi, P., Sultana, M., Al-Harbi, S., Ibrahim, M., Al-Nuaim, A., Ahmed, M., Amin, T., Al-Fehaily, M., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1717 · Cited by 169
Jo, Y. S., Li, S., Song, J. H., Kwon, K. H., Lee, J. C., Rha, S. Y., Lee, H. J., Sul, J. Y., Kweon, G. R., Ro, H.-K., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2836 · Cited by 160
Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
Shah, D. R., Shah, R. R., & Morganroth, J. (2013) · Drug Safety · doi:10.1007/s40264-013-0050-x · Cited by 160
2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer
Schlumberger, M., Bastholt, L., Dralle, H., Jarzab, B., Pacini, F., & Smit, J. W. A. (2012) · European Thyroid Journal · doi:10.1159/000336977 · Cited by 158
Sosa, J. A., Elisei, R., Jarząb, B., Balkissoon, J., Lu, S.-P., Bal, C., Marur, S., Gramza, A. W., Ben‐Yosef, R., Gitlitz, B. J., et al. (2013) · Thyroid · doi:10.1089/thy.2013.0078 · Cited by 151
Self-citationMultikinase inhibitors: a new option for the treatment of thyroid cancer
Gild, M. L., Bullock, M., Robinson, B. G., & Clifton-Bligh, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.141 · Cited by 146
Godbert, Y., de Figueiredo, B. H., Bonichon, F., Chibon, F., Hostein, I., Pérot, G., Dupin, C., Daubech, A., Belleannée, G., Gros, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6596 · Cited by 142
Capp, C., Wajner, S. M., Siqueira, D. R., Brasil, B. A., Meurer, L., & Maia, A. L. (2010) · Thyroid · doi:10.1089/thy.2009.0417 · Cited by 140
Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer
Ji, J. H., Oh, Y. L., Hong, M. E., Yun, J. W., Lee, H.-W., DeokGeun, K., Ji, Y., Duk-Hwan, K., Park, W., Shin, H., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005467 · Cited by 139
Torlontano, M., Crocetti, U., Augello, G., D’Aloiso, L., Bonfitto, N., Varraso, A., Dicembrino, F., Modoni, S., Frusciante, V., Di Giorgio, A., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1185 · Cited by 138
Elisei, R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.7.3211 · Cited by 137
Self-citationCopland, J. A., Marlow, L. A., Kurakata, S., Fujiwara, K., Wong, A., Kreinest, P. A., Williams, S. F., Haugen, B. R., Klopper, J. P., & Smallridge, R. C. (2005) · Oncogene · doi:10.1038/sj.onc.1209267 · Cited by 134
Dadu, R., Shah, K. B., Busaidy, N. L., Waguespack, S. G., Habra, M. A., Ying, A. K., Hu, M. I.-N., Bassett, R. L., Jiménez, C., Sherman, S. I., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2246 · Cited by 131
Locati, L. D., Licitra, L. F., Agate, L., Ou, S. I., Boucher, A., Jarząb, B., Qin, S., Kane, M. A., Wirth, L. J., Chen, C., et al. (2014) · Cancer · doi:10.1002/cncr.28766 · Cited by 124
Self-citationA Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer
Lira, M. E., Choi, Y., Lim, S. M., Deng, S., Huang, D., Ozeck, M., Han, J., Jeong, J. Y., Shim, H. S., Cho, B. C., et al. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.11.007 · Cited by 121
Bible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., Rubin, J., Karlin, N. J., Sideras, K., Morris, J. C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3713 · Cited by 120
Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer
Orlandi, F., Caraci, P., Berruti, A., Puligheddu, B., Pivano, G., Dogliotti, L., & Angeli, A. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058984 · Cited by 119
Smallridge, R. C., Copland, J. A., Brose, M. S., Wadsworth, J. T., Houvras, Y. J., Menefee, M. E., Bible, K. C., Shah, M. H., Gramza, A. W., Klopper, J. P., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1106 · Cited by 114
Higher rate of BRAF mutation in papillary thyroid cancer over time: A single‐institution study
Mathur, A., Moses, W., Rahbari, R. M., Khanafshar, E., Duh, Q., Clark, O. H., & Kebebew, E. (2011) · Cancer · doi:10.1002/cncr.26072 · Cited by 112
Molecular Analysis of Thyroid Tumors
Bhaijee, F., & Nikiforov, Y. E. (2011) · Endocrine Pathology · doi:10.1007/s12022-011-9170-y · Cited by 112
Intragenic Mutations in Thyroid Cancer
Sobrinho-Simões, M. A., Máximo, V., Rocha, A. S., Trovisco, V., Castro, P., Preto, A., Lima, J. P., & Soares, P. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.02.004 · Cited by 109
Lin, C., Whang, E. E., Donner, D. B., Du, J., Lorch, J. H., He, F., Jiang, X., Price, B. D., Moore, F. D., & Ruan, D. T. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0162 · Cited by 108
Ballerini, P. F., Struski, S., Cresson, C., Prade, N., Toujani, S., Deswarte, C., Dobbelstein, S., Petit, A., Lapillonne, H., Gautier, E., et al. (2012) · Leukemia · doi:10.1038/leu.2012.109 · Cited by 107
Expression of hypoxia-inducible factor 1α in thyroid carcinomas
Burrows, N., Resch, J., Cowen, R. L., von Wasielewski, R., Hoang‐Vu, C., West, C., Williams, K. J., & Brabant, G. E. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0251 · Cited by 107
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years
Romei, C., Fugazzola, L., Puxeddu, E., Frasca, F., Viola, D., Muzza, M., Moretti, S., Nicolosi, M. L., Giani, C., Cirello, V., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1269 · Cited by 99 · cited 1×
“The prevalence of RET/PTCpositive cases is approximately 20%, and it has apparently been decreasing in recent decades (Romei et al. 2012).”
BackgroundSelf-citationMarotta, V., Ramundo, V., Camera, L., Prete, M. D., Fonti, R., Esposito, R., Palmieri, G., Salvatore, M., Vitale, M., Colao, A., et al. (2012) · Clinical Endocrinology · doi:10.1111/cen.12057 · Cited by 99
Advances in the follow-up of differentiated or medullary thyroid cancer
Elisei, R., & Pinchera, A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.38 · Cited by 91 · cited 1×
“Rates are 95 and 80% after 35–40 years for PTC and FTC, respectively; 65% for MTC after 10 years; less than 20% for PDTC at 5 years; and less than 10% for ATC at 6 months after the initial diagnosis (Elisei & Pinchera 2012).”
BackgroundSelf-citationMedullary Thyroid Cancer: An Immunohistochemical and Humoral Study Using Six Separate Antigens
Pacini, F., Basolo, F., Elisei, R., Fugazzola, L., Cola, A., & Pinchera, A. (1991) · American Journal of Clinical Pathology · doi:10.1093/ajcp/95.3.300 · Cited by 91
Self-citationSynergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
Jin, N. Y., Jiang, T., Rosen, D. M., Nelkin, B. D., & Ball, D. W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0933 · Cited by 90
RET Fusion as a Novel Driver of Medullary Thyroid Carcinoma
Grubbs, E. G., Ng, P. K., Bui, J. H., Busaidy, N. L., Chen, K., Lee, J. E., Lu, X., Lu, H., Meric‐Bernstam, F., Mills, G. B., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4153 · Cited by 90
A Missing Link in Genotype-Directed Cancer Therapy
Bernards, R. (2012) · Cell · doi:10.1016/j.cell.2012.10.014 · Cited by 86 · cited 1×
“In fact, blocking a single pathway has been shown to lead to the activation of other pathways that then overcome the drug’s effects (Bernards 2012).”
BackgroundGenetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
Soares, P., Lima, J., Preto, A., Castro, P., Vinagre, J., Celestino, R., P. Couto, J., Prazeres, H., Eloy, C., Maximo, V., et al. (2011) · Current Genomics · doi:10.2174/138920211798120853 · Cited by 85
Papotti, M. G., Olivero, M., Volante, M., Negro, F., Prat, M., Comoglio, P. M., & Renzo, M. F. D. (2000) · Endocrine Pathology · doi:10.1385/ep:11:1:19 · Cited by 85
Juweid, M. E., Hajjar, G., Swayne, L. C., Sharkey, R. M., Suleiman, S., Herskovic, T., Pereira, M. A., Rubin, A. D., & Goldenberg, D. M. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990415)85:8<1828::aid-cncr25>3.0.co;2-h · Cited by 84
Scarpino, S., d’Alena, F. C., Napoli, A. D., Pasquini, A., Marzullo, A., & Ruco, L. (2004) · The Journal of Pathology · doi:10.1002/path.1522 · Cited by 79
Jin, N. Y., Jiang, T., Rosen, D. M., Nelkin, B. D., & Ball, D. W. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0662 · Cited by 78
Liu, D., Liu, Z., JIANG, D., Dackiw, A. P. B., & Xing, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0097 · Cited by 75
Juweid, M., Hajjar, G., Stein, R., Sharkey, R. M., Herskovic, T., Swayne, L. C., Suleiman, S., Pereira, M. A., Rubin, A., & Goldenberg, D. M. (2000) · PubMed · Cited by 71
Brose, M. S., Nutting, C. M., Jarząb, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardière, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.4 · Cited by 70
Self-citationBauer, A. J., Terrell, R., Doniparthi, N. K., Patel, A. D., Tuttle, R. M., Saji, M., Ringel, M. D., & Francis, G. L. (2002) · Thyroid · doi:10.1089/105072502320908286 · Cited by 70
Pazopanib Enhances Paclitaxel-Induced Mitotic Catastrophe in Anaplastic Thyroid Cancer
Isham, C. R., Bossou, A. R., Negron, V. C., Fisher, K. E., Kumar, R., Marlow, L. A., Lingle, W. L., Smallridge, R. C., Sherman, E. J., Suman, V. J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004358 · Cited by 69
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer
Worden, F. P., Faßnacht, M., Shi, Y., Hadjieva, T., Bonichon, F., Gao, M., Fugazzola, L., Ando, Y., Hasegawa, Y., Park, D. J., et al. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0252 · Cited by 68
Liu, D., Xing, J., Trink, B., & Xing, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25304 · Cited by 61
Reversal of Cushing's Syndrome by Vandetanib in Medullary Thyroid Carcinoma
Baudry, C., Paepegaey, A. C., & Groussin, L. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1301428 · Cited by 61
Brose, M. S., Nutting, C. M., Jarząb, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardière, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.4 · Cited by 61 · cited 1×
“…majority of AEs are easily prevented or managed with drug treatment, but in a nonnegligible percentage of cases, dose reduction (up to 79% for cabozantinib), interruption (up to 66.2% for sorafenib), or withdrawal (up to 26% for lenvatinib) was needed in clinical trials (Brose 2013, Elisei et al.”
BackgroundInfluentialSelf-citationKoguchi, Y., Hoen, H. M., Bambina, S., Rynning, M. D., Fuerstenberg, R. K., Curti, B. D., Urba, W. J., Milburn, C. M., Bahjat, F. R., Korman, A. J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2303 · Cited by 59
BRAF mutation influences hypoxia-inducible factor-1α expression levels in papillary thyroid cancer
Zerilli, M., Zito, G., Martorana, A., Pitrone, M., Cabibi, D., Cappello, F., Giordano, C. S. D. S., & Rodolico, V. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.86 · Cited by 59
Arao, T., MATSUMOTO, K. Y., Furuta, K., Kudo, K., Kaneda, H., Nagai, T., Sakai, K., Fujita, Y., Tamura, D., Aomatsu, K., et al. (2011) · PubMed · Cited by 55
Wang, S., Pashtan, I. M., Tsutsumi, S., Xu, W., & Neckers, L. (2009) · Cell Cycle · doi:10.4161/cc.8.13.8861 · Cited by 46
Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy
Lin, S., Huang, Y., Lin, J., Chou, T., Hsueh, C., & Wong, R. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046726 · Cited by 46 · cited 1×
“More recently, due to the relative inefficacy of this group of compounds in treating solid tumors, a new drug (BEZ235) targeting both PI3K and mTOR has been developed (Lin et al. 2012).”
BackgroundStein, B. L., & Smith, B. D. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.05.003 · Cited by 42 · cited 1×
“…the discovery of imatinib resistance mutations, new drugs, such as dasatinib, nilotinib, and bosutinib, have been developed for use as second- and third-line therapies for use in treating CML patients after the development of escape from imatinib (Stein & Smith 2010, Amsberg & Koschmieder 2013).”
BackgroundSmyth, P. C., Finn, S. P., Cahill, S., O’Regan, E. M., Flavin, R., O’Leary, J. J., & Sheils, O. M. (2005) · International Journal of Surgical Pathology · doi:10.1177/106689690501300101 · Cited by 42
Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia
Koschmieder, S., & Keller-v.Amsberg (2013) · OncoTargets and Therapy · doi:10.2147/ott.s19901 · Cited by 40 · cited 1×
“…the discovery of imatinib resistance mutations, new drugs, such as dasatinib, nilotinib, and bosutinib, have been developed for use as second- and third-line therapies for use in treating CML patients after the development of escape from imatinib (Stein & Smith 2010, Amsberg & Koschmieder 2013).”
BackgroundBarroso‐Sousa, R., Lerário, A. M., Evangelista, J., Papadia, C., Lourenço, D. M., Lin, C. S., Kulcsar, M. A. V., Fragoso, M. C. B. V., & Hoff, A. O. (2014) · Thyroid · doi:10.1089/thy.2013.0571 · Cited by 38
Karaca, Z., Tanrıverdi, F., Unluhizarci, K., Ozturk, F., Gökahmetoğlu, S., Elbüken, G., Çakır, I., Bayram, F., & Keleştimur, F. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0967 · Cited by 37
Schlumberger, M. J., Elisei, R., Müller, S. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.6012 · Cited by 34
Self-citationKim, E., Matsuse, M., Saenko, V., Suzuki, K., Ohtsuru, A., Mitsutake, N., & Yamashita, S. (2012) · Thyroid · doi:10.1089/thy.2011.0380 · Cited by 32
15TH INTERNATIONAL THYROID CONGRESS PROGRAM AND MEETING ABSTRACTS
Assadi Porter, F., Reiland, H., Carnicelli, V., Sabatini, M., Rogowski, M. P., Selen, E., Tonelli, M., Saba, A., Lorenzini, L., Ghelardoni, S., et al. (2015) · Thyroid · doi:10.1089/thy.2015.29004.abstracts · Cited by 23
Marques, P., Vieira, M. D. S., & Bugalho, M. J. (2014) · Endocrine · doi:10.1007/s12020-014-0352-5 · Cited by 17
Response to sorafenib treatment in advanced metastatic thyroid cancer
Pitoia, F. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000002839 · Cited by 15 · cited 1×
“2013, Pitoia 2014).”
Bible, K. C., Cote, G. J., Demeure, M. J., Elisei, R., Jhiang, S. M., & Ringel, M. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2818 · Cited by 14
Self-citationIsham, C. R., Netzel, B. C., Bossou, A. R., Milosevic, D., Cradic, K. W., Grebe, S. K. G., & Bible, K. C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2658 · Cited by 12
Cited by
Chen, H., Luo, D., Zhang, L., Lin, X., Luo, Q., Yi, H., Wang, J., Yan, X., Li, B., Chen, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17398 · Cited by 29
“Although these two multi-targeted TKIs improve patient response in terms of progression free survival (PFS), the data showing improvement in overall survival are very limited [14].”
Background
Metadata
- Authors
- Viola, D., Valerio, L., Molinaro, E., Agate, L., Bottici, V., Biagini, A., Lorusso, L., Cappagli, V., Pieruzzi, L., Giani, C., Sabini, E., Passannati, P., Puleo, L., Matrone, A., Pontillo-Contillo, B., Battaglia, V., Mazzeo, S., Vitti, P., & Elisei, R.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2016-04
- Volume
- 23
- Issue
- 4
- Pages
- R185-R205
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2400741439
- Cited by
- 191
- References
- 121
- FWCI
- 26.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.